Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward
06:05pm, Friday, 05'th Sep 2025
Fractyl Health's Revita offers a one-time procedure to maintain GLP-1 weight loss, with pivotal 45-patient trial data expected imminently. Early open-label results show Revita may significantly reduce
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
08:28am, Friday, 05'th Sep 2025
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared
BELVIDERE, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA)
NEW YORK , Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical prog
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in partici
Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy
11:51am, Thursday, 28'th Aug 2025
Eli Lilly's explosive growth is driven by GLP-1 drugs Mounjaro and Zepbound, with tirzepatide becoming a historic best-seller in obesity and diabetes. President Trump's aggressive drug pricing reforms
Is Global Partners (GLP) Stock Undervalued Right Now?
10:40am, Thursday, 28'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
11:55am, Wednesday, 27'th Aug 2025
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)
10:00am, Wednesday, 27'th Aug 2025
This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around Federal
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
12:10pm, Tuesday, 26'th Aug 2025
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity o
Hims & Hers: Personalized Care To Sustain Revenue Growth Despite GLP-1 Hiccup
11:51am, Friday, 22'nd Aug 2025
I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract w
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
07:32am, Wednesday, 20'th Aug 2025
jetcityimage / iStock Editorial via Getty Images Eli Lilly stock was up more than 50% in 2024, before declining in 2025.
GLP-1 drug Wegovy approved to treat liver disease, what's driving Q2 earnings results
01:47pm, Monday, 18'th Aug 2025
Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
09:00am, Saturday, 16'th Aug 2025
The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY202
